News and Trends 7 Sep 2015
A Slice of Europe: MD Anderson looks to invest in EU Immuno-Oncology
MD Anderson is expanding its Immatics sharehold to spawn new Houston-based subsidiary Immatics US through investing into a $60M (€54M) pot. Also partnering up with French CAR-T pioneers Cellectis, and collaborating with German Merck, MD Anderson is seemingly wanting to immerse itself in the European immuno-oncology field. As a shareholder in the German cancer immunotherapy […]